The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
The field of exercise science is rapidly evolving through the integration of omics technologies, giving rise to promising subdisciplines such as enduromics ...
Abstract: Cerebral stroke, as a disease resulting from cerebral circulatory disorders, continues to have a stubbornly high incidence rate. With the ongoing advancements in rehabilitation technology, ...
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...
Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...
Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Abstract: Molecular communication (MC) is a bio-inspired communication paradigm that utilizes molecules to transfer information and offers a robust framework for understanding biological signaling ...
This study presents a valuable advance in reconstructing naturalistic speech from intracranial ECoG data using a dual-pathway model. The evidence supporting the claims of the authors is solid, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results